Report cover image

Global Pharmaceuticals Outlook, 2022

Publisher Frost & Sullivan
Published Mar 08, 2022
Length 60 Pages
SKU # MC17020219

Description

Global Pharmaceuticals Outlook, 2022

Frost & Sullivan offers an outlook for the global pharmaceuticals market for 2022-2026, including emerging trends and growth opportunities. Prioritizing booster doses over initial dose coverage is negatively impacting the global mitigation of the COVID-19 pandemic, which is resulting in severe implications on health and social and economic well-being and delaying endemicity. The ongoing pandemic has accelerated pharma and biotech companies' transformation, and clinical trial decentralization, data-driven R&D, the digitalization of the supply chain, and outsourcing have taken center stage.

The industry will focus on supply chain resilience and the adoption of innovative technologies to improve efficiency while ensuring that healthcare remains precise, preventive, and outcome-based in the promotion of social and financial inclusion. In 2021, the emphasis was on COVID-19 in terms of drug research and therapy administration; this trend is expected to change by the end of 2022, and oncology and CNS are expected to become leading growth areas for the pharma industry. Value-based care will take center stage and lead to a shift to platform- and data-based drug discovery and development models.

KEY ISSUES ADDRESSED

What is the size of the global pharmaceuticals industry from 2022 to 2026?
What are the dynamics around COVID-19 vaccination deployment and the path to endemicity?
How are advancements such as decentralization, blockchain, and new modalities driving the transformation of the pharmaceuticals value chain?
What is the current and future therapeutic, R&D, and investment outlook and how is it evolving?
Which growth opportunities can ecosystem participants leverage in the near future?

Table of Contents

60 Pages
    • Key Highlights
    • Regional Impact of the COVID-19 Pandemic
    • Top Pharmaceuticals Industry Predictions for 2022
    • Why Is It Increasingly Difficult to Grow?
    • The Strategic Imperative 8™
    • The Impact of the Top Three Strategic Imperatives on the Pharmaceuticals Industry
    • Growth Opportunities Fuel the Growth Pipeline Engine™
    • Market Segmentation and Scope
    • Key Trend 1—Strategies to Fight Long COVID-19
    • Key Trend 2—Data-driven R&D Approach
    • Key Trend 3—Intense Conflict between Affordability and Access
    • Key Trend 4—Biologics Driving Manufacturing Capacity and Capability Expansion
    • Global Pharmaceuticals Industry—R&D Expenditure Outlook
    • Key Therapeutic Areas Outlook
    • Biopharmaceuticals' VC Investments and M&A Outlook
    • Global GDP Growth
    • 2022 Scenario Analysis—Quarterly Global Growth
    • Supply Chain Disruptions—Impact Analysis
    • Sustainability Initiatives—Impact Analysis
    • Global Pharmaceuticals Industry—Historic Sales and Forecast
    • Segment Performance—Historic Sales and Forecast
    • Revenue Forecast by Region
    • Prediction 1
    • Prediction 2
    • Prediction 3
    • Prediction 4
    • Prediction 5
    • Small-molecules Market Snapshot, 2022
    • Small-molecules Market—Companies to Watch
    • Biologics Market Snapshot, 2022
    • Biologics Market—Companies to Watch
    • Growth Opportunity 1—Innovative Formulation and Delivery Technologies for RNA Therapeutics, 2022
    • Growth Opportunity 2—Contract Research, Development, and Manufacturing Services to Support Emerging Biopharmaceuticals Companies in Asia-Pacific, 2022
    • Growth Opportunity 3—Digital Therapeutics to Support Evidence-based Treatment and Medication Adherence in the EU, 2022
    • Key Concluding Thoughts
    • Market Definition—Pharmaceuticals and Biotechnology
    • Your Next Steps
    • Why Frost, Why Now?

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us